Simcere Pharmaceutical Group Reports Third Quarter 20...( Net Income Increased 73% Year...),Health

Net Income Increased 73% Year-over-year or 89% Year-to-date

NANJING, China, Nov. 5 /Xinhua-PRNewswire-FirstCall/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today reported unaudited financial results for the quarter ended September 30, 2007.

Third Quarter 2007 Highlights

-- Total revenue increased to RMB323.4 million (US$43.2 million) from

RMB223.8 million in the third quarter of 2006, representing a 44.5 %

year-over-year growth;

-- Net income increased to RMB73.1 million (US$9.8 million) from RMB42.3

million in the third quarter of 2006, representing a 72.9% year-over-

year growth; and

-- Gross margin increased to 81.7% from 79.0% in the third quarter of

2006. The improvement in gross margin reflects continuous increases

in sales of higher gross margin products.

Mr. Jinsheng Ren, Chairman and CEO of Simcere Pharmaceutical Group, commented: "This has been a solid quarter for Simcere. Our lead products Endu and Bicun achieved 377.3% and 83.8% year-over-year growth respectively, driving our business forward and achieving an overall year-over-year growth of 44.5% in terms of revenue, 72.9% in terms of net income, and 38.3% in terms of basic earnings per share. We have also made progress in stabilizing the performance of our generic products during this quarter. We expect the momentum of Endu, Bicun, and other generic products to continue.

In addition, we completed the acquisition of 51% ownership interest in Boda Pharmaceutical on October 1st. After this transaction, we have
'/>"/>